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Abstract
The neurofibromatoses represent two of the most
common inherited tumor predisposition syndromes
affecting the nervous system. Individuals with neuro-
fibromatosis 1 (NF1) are prone to the development of
astrocytomas and peripheral nerve sheath tumors
whereas those affected with neurofibromatosis 2 (NF2)
develop schwannomas and meningiomas. The develop-
ment of traditional homozygous knockout mice has
provided insights into the roles of the NF1 and NF2
genes during development and in differentiation, but has
been less instructive regarding the contribution of NF1
and NF2 dysfunction to the pathogenesis of specific
benign and malignant tumors. Recent progress employ-
ing novel mouse targeting strategies has begun to il-
luminate the roles of the NF1 and NF2 gene products
in themolecular pathogenesis ofNF-associated tumors.
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Introduction
The neurofibromatoses comprise two distinct clinical con-
ditions, neurofibromatosis 1 (NF1) and neurofibromatosis 2
(NF2). Each of these disorders shares the common feature
of benign and malignant tumor predisposition; however, the
tumor types and clinical manifestations are markedly different
[1 ]. In addition, the genetic basis for NF1 is clearly distinct
from that of NF2, in that the NF1 and NF2 genes encode
unique and markedly dissimilar gene products, neurofibromin
and merlin, located on chromosomes 17 and 22, respec-
tively. Significant progress toward elucidating the molecular
pathogenesis of NF1 and NF2 has resulted from the
identification of their associated genes; however, our ability
to design targeted therapies for these disorders is heavily
dependent on the development of relevant and accurate
preclinical mouse models of the specific clinical features of
NF1 and NF2. This review will focus on the development and
refinement of mouse models for NF1 and NF2.
Clinical Disorders
Neurofibromatosis 1
Neurofibromatosis 1 is the most common autosomal
dominant disorder affecting the nervous system. Affected
individuals are prone to the development of both benign and
malignant tumors, including peripheral nerve sheath tumors
(neurofibromas and malignant peripheral nerve sheath
tumors [MPNSTs]), astrocytomas (gliomas), leukemias,
and pheochromocytomas [2]. Aside from the tumor pheno-
types, individuals with NF1 also exhibit pigmentary abnor-
malities, including hyperpigmented skin macules (cafe´ -
au- lait macules), skinfold freckling, and iris hamartomas
(Lisch nodules). In addition, children with NF1 often have
skeletal defects ( long bone deformities, scoliosis, sphenoid
wing dysplasia) and learning disabilities. The most common
tumor in NF1 is the benign peripheral nerve sheath tumor
(neurofibroma) composed of Schwann cells, fibroblasts, and
mast cells [3 ]. The onset of these tumors typically coincides
with the onset of puberty and they continue to appear
throughout adulthood. These tumors do not transform into
malignant tumors, but carry a tremendous cosmetic burden.
Approximately 25% to 30% of individuals with NF1 will
develop a more extensive neurofibroma (plexiform neuro-
fibroma) that is thought to represent a congenital lesion.
These tumors, although also benign, may grow to enormous
proportions, develop a rich blood supply, and transform into
aggressive MPNSTs. Within the central nervous system
(CNS), the most common tumor is the optic pathway glioma,
seen in 15% of children with NF1 [4]. This low-grade pilocytic
astrocytoma is rarely fatal, but can lead to visual loss and
hypothalamic dysfunction. In contrast to the neurofibroma,
the growth of these tumors appear to be limited to the first
decade of life, with rare examples of continued growth in
adulthood.
Although rare, myeloid malignancies, such as myelodys-
plastic syndrome (MDS) and juvenile chronic myeloid
leukemia (JCML), are overrepresented in children with
NF1 [5]. Boys tend to be affected more often than girls.
Pheochromocytoma, a tumor of the adrenal gland, is more
common in individuals with NF1. Despite its association
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with NF1, it affects less than 1% of individuals with the
disorder.
Children with NF1 also frequently exhibit specific learning
disabilities [6 ]. Approximately 40% to 60% of children with
NF1 will manifest below average performance on stand-
ardized IQ tests and demonstrate difficulties with traditional
learning paradigms. These children are not retarded, but
have specific deficits in learning.
Neurofibromatosis 2
Neurofibromatosis type 2 (NF2), also called bilateral
acoustic neurofibromatosis, is a dominantly inherited genetic
disorder characterized by the development of bilateral
vestibular schwannomas, schwannomas of other cranial,
spinal, and cutaneous nerves, as well as cranial and spinal
meningiomas and ependymomas [1,2,7 ]. The incidence
of NF2 is much lower than NF1, affecting approximately
1/40,000 individuals (vs 1/3,000 for NF1). Bilateral vestib-
ular schwannomas and multiple spinal schwannomas are
diagnostic of NF2. These benign Schwann cell neoplasms
(World Health Organization [WHO] grade I) develop in the
majority of NF2 patients and are the hallmark of the disease.
Occasionally, schwannomas may also arise on other
sensory nerves, including the fifth ( trigeminal ) cranial nerve
and spinal dorsal roots. Most vestibular schwannomas are
located at the internal auditory meatus or within the internal
auditory canal and slowly grow toward the cerebellopontine
angle to result in increased intracranial pressure, cranial
nerve dysfunction, or cerebellar herniation. Malignant pro-
gression of schwannomas to MPNSTs is a rare event.
Multiple meningiomas are the second most common
tumor in NF2, occurring in nearly half of all affected
individuals. These benign neoplasms (WHO grade I),
composed of neoplastic arachnoidal cap cells, also grow
slowly and elicit neurological signs and symptoms by
compression of adjacent structures. Because of their
tendency to invade brain tissue, recur after resection, and
spread along the leptomeninges to involve multiple regions,
some meningiomas represent a therapeutic challenge.
Other CNS tumors include ependymomas and astrocyto-
mas. Occurrence of gliomas is less frequent in NF2 than in
NF1 patients and most of these neoplasms are morpholog-
ically benign intramedullary spinal tumors. Dysplastic CNS
lesions, such as glial microhamartomas, schwannosis,
meningioangiomatosis and ependymal ectopias are also
encountered in the context of NF2.
Pigmentary abnormalities are uncommonly seen in
patients with NF2. About 60% to 80% of NF2 patients
develop juvenile posterior subcapsular lens opacities. There-
fore, lens changes are considered a valuable, early marker of
NF2 in individuals at risk.
NF1 Gene and Function
The identification of the NF1 gene ushered in a new era of
molecular understanding of the pathogenesis of this disor-
der. The NF1 gene on chromosome 17q11.2 spans 350
kilobases (kb) of genomic DNA and encodes an 11- to 13-
kb mRNA [8-11]. The protein product, neurofibromin, is a
large 220- to 250-kDa cytoplasmic protein expressed
predominantly in neurons, Schwann cells, oligodendrocytes,
astrocytes, leukocytes and the adrenal medulla (Figure 1 )
[12-14]. Neurofibromin has been shown to associate with
the actin and microtubule cytoskeleton, but lacks conven-
tional binding motifs for known protein–protein associations
[15-17]. Analysis of the predicted NF1 amino acid sequence
revealed a small central region of the protein with sequence
similarity to a family of proteins involved in the inactivation of
RAS (GTPase-activating protein or GAPs) [18]. RAS is an
important intracellular signaling molecule, which mediates
cell proliferation in some cells (e.g., astrocytes and
leukocytes) and differentiation in other cell types (e.g.,
neurons and Schwann cells ) [19]. The association of the
RAS molecule with guanosine phosphates dictates RAS
activity: RAS is active when bound to GTP and inactive when
associated with GDP (Figure 1 ). RAS-GAP molecules, like
neurofibromin, function as negative regulators of RAS, by
accelerating the intrinsic GTPase activity of RAS, thereby
converting RAS from an active GTP-bound form to inactive
RAS-GDP. Because RAS promotes cell proliferation and
transformation in some cells, neurofibromin is believed to
function as a tumor suppressor by inactivating RAS
mitogenic signaling.
Individuals with NF1 are born with one mutated or
nonfunctional NF1 gene. Similar to the retinoblastoma
paradigm, tumors in NF1 form only when the one remaining
wild- type NF1 allele is inactivated by somatic mutation [20].
This ‘‘two-hit’’ hypothesis has been validated in tumor
tissues from individuals with NF1, in which both the somatic
and germline NF1 mutations were identified, resulting in
no neurofibromin expression (Figure 2 ). In agreement
with the proposed function of neurofibromin as a RAS
Figure 1. Neurofibromin, the product of the NF1 gene, encodes a 2818 amino
acid protein that contains a central region with RAS GTPase -activating
protein (GAP ) activity. The GAP domain is denoted by the shaded area. In
addition to this functionally important domain, neurofibromin contains three
alternatively spliced exons ( 9a, 23a, and 48a ). Neurofibromin, like other GAP
molecules, accelerates the conversion of active GTP-bound RAS to the
inactive GDP-bound form. Guanosine nucleotide replacing factors (GNRFs )
reactivate RAS by exchanging GDP for GTP.
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regulator, loss of neurofibromin in NF1-associated
tumors is associated with elevated levels of activated
RAS [21-25].
The NF1 gene has three alternatively spliced exons, 9a,
23a, and 48a, which are differentially expressed in specific
tissue types. Exon 9a–containing neurofibromin is restricted
to neurons of the forebrain beginning in early postnatal
development [26]. Neurofibromin containing exon 48a is
only expressed in muscle tissues [27]. It is not known what
functions are gained or lost by the insertion of exons 9a or
48a. Lastly, exon 23a inserts a unique 21 amino acids into
the GAP domain of neurofibromin and results in a neuro-
fibromin protein with reduced GAP activity [28]. NF1 -23a
mRNA is found in many tissues during development and in
the adult [29].
NF2 Gene and Function
The identification of germline mutations in NF2 patients
provided the genetic evidence that this condition is caused
by germline alterations in theNF2 gene [30,31]. Themajority
of germline and somatic mutations in the NF2 gene, resulting
in either a premature termination codon, a splicing alteration,
or a frameshift, lead to the production of a truncated protein.
In- frame deletions and missense mutations have also been
found, suggesting that the alteration of particular functional
domains may abolish the function of the NF2 protein. In
tumors from patients with NF2, mutations in both NF2 alleles
have been identified, concomitant with loss of NF2 protein
expression. These observations indicate that NF2 is a tumor
suppressor gene, although the detailed mechanism by which
NF2 mutation leads to transformation of Schwann cells is
largely unknown.
The product of the NF2 gene has been termed merlin [31]
or schwannomin [30]. Analysis of the predicted protein
sequence indicates that merlin belongs to the band 4.1 family
of cytoskeleton-associated proteins and exhibits the great-
est similarity to a subset of proteins in this family, notably the
ezrin, radixin, and moesin (ERM) proteins [32]. The NF2
gene encodes a 595 amino acid protein with 17 exons
(Figure 3A ). Alternative splicing yields at least two merlin
isoforms, type 1 ( lacking exon 16) and type 2 that contains
exon 16, but lacks exon 17 sequences, owing to a premature
termination signal within exon 16 [33]. These NF2 isoforms
are conserved in mouse [34] and rat [35]. There are three
predicted regions with potential functional significance: The
FERM domain (residues 1–302) and the alpha helical
region (residues 303–479) are shared among all ERM
family members whereas the carboxyl terminal domain of
merlin is unique and lacks a conventional actin binding motif,
found in other ERM proteins. Merlin is expressed in Schwann
cells, neurons, lens fibers, blood vessels, and leptomenin-
geal cells in the adult, but exhibits a more widespread tissue
expression pattern during embryonic development. The
FERM homology domain of merlin appears to be the main
determinant that localizes the protein to the plasma
membrane [36]. Mutations that lead to an interstitial deletion
in this domain have been observed both in the germline of
NF2 patients and in sporadic schwannomas, meningiomas,
and mesotheliomas. Mutant proteins lacking exon 2 or exons
2 and 3 do not interact with the plasma membrane, and are
diffusely distributed in the cytoplasm [36,37].
Merlin, like other ERM proteins, exists in two conforma-
tions, dictated by its ability to form an intramolecular
Figure 3. Structure of the NF2 gene product, merlin. (A ) Merlin is structurally
related to the ERM subfamily of Protein 4.1 molecules, including ERM. Merlin
contains an amino terminal FERM domain and a central predicted alpha
helical domain followed by a unique carboxyl terminal region (CTD) that is not
conserved among ERM family members. The conventional ERM actin -
binding region is not contained within the CTD of merlin. The NF2 gene has an
alternatively spliced exon (exon 16 ) that encodes 11 unique residues followed
by a termination codon, which results in a truncated protein lacking exon 17
sequences. (B ) Merlin exists in ‘‘open’’ and ‘‘closed’’ conformations that may
be dictated by phosphorylation. In the ‘‘open’’ conformation, merlin is defective
as a negative growth regulator, but, in the closed self - associated form is
active and binds to CD44 to mediate growth suppression.
Figure 2. Knudson ‘‘two -hit’’ hypothesis for tumor suppressor genes. In
sporadic cancers, there is sequential inactivation of both copies of a given
tumor suppressor gene, whereas in individuals with an inherited cancer
syndrome, only one additional genetic ‘‘hit’’ is required. Because individuals
with NF1 or NF2 start life with a germline mutation in the NF1 or NF2 genes,
respectively, the only genetic event required for tumor formation is inactivation
of the one remaining functional NF1 or NF2 gene. Loss of NF1 or NF2
expression results in increased cell proliferation that predisposes to tumor
formation.
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complex. Merlin forms an intramolecular association using
residues in the extreme carboxyl terminus (exon 17) to
bind to a region at the end of the FERM domain (residues
302–308) [38-40]. In addition to the N-term:C- term intra-
molecular complex, merlin also forms another intramolecular
association within the FERM domain, which is disturbed by
mutations within exons 2 and 3 [40,41]. Failure to form either
an N- term:C-term or N-term:N- term association leads to
an inactive growth suppressor protein (Figure 3B ). The
crystal structure of the merlin FERM domain has been
recently determined and provides physical evidence for the
biochemical studies demonstrating that intramolecular asso-
ciations within the FERM domain are important for merlin
function [42].
In addition, there is a good correlation between the ability
of the various merlin isoforms to form intramolecular
interactions and the growth suppressive activity of these
molecules. In particular, merlin isoform I, which is the isoform
able to inhibit growth when exogenously expressed in rat
schwannoma cells, forms both intramolecular interactions
[38,40]. However, merlin isoform II, which lacks the region
encoded by exon 17 required for proper folding, does not
affect schwannoma cell growth. Similarly, some rare merlin
isoforms or naturally occurring missense mutants with
variant N- terminal regions likewise exhibit a constitutively
‘‘open’’ conformation and lack growth-suppressive activity
[43,44].
Merlin folding is also dictated by the phosphorylation state
of merlin: Hyperphosphorylation of merlin leads to protein
unfolding and is associated with an ‘‘inactive’’ molecule
whereas the ‘‘active’’ merlin growth suppressor is under-
phosphorylated and associates with specific interactors to
modulate cell growth [45]. In keeping with the proposed
function of merlin in signal transduction events beginning at
the plasma membrane, merlin interacts with the trans-
membrane protein CD44. Merlin associates with the cyto-
plasmic tail of CD44 preferentially in its hypophosphorylated
‘‘active’’ form [45]. Under growth-permissive conditions,
merlin becomes phosphorylated and inactive and does not
associate with CD44. In situations permissive for growth
arrest, merlin is hypophosphorylated and can bind to CD44
to abrogate CD44 mitogenic signaling. Recent work demon-
strated that merlin is phosphorylated in a Rac1/cdc42-
dependent fashion [46-48]. The discovery of the link
between a well -known signaling pathway and merlin
represents an important step toward understanding the
regulation of merlin growth suppression.
One approach to defining how merlin functions involves
the identification of molecules that specifically interact with
merlin and could potentially transduce its growth inhibitory
signal. Several merlin interacting proteins have been iden-
tified, including II -spectrin [49], CD44 [50], sodium–
hydrogen exchange regulator factor (NHE-RF) [51],
schwannomin- interacting protein-1 (SCHIP-1) [52], hep-
atocyte growth factor–regulated tyrosine kinase substrate
(HRS) [53], actin [43], and 1- integrin [54]. NHE-RF
interacts with all ERM family members [55] and is therefore
unlikely to be a specific merlin signaling molecule. SCHIP-1
Figure 4. Strategies for Nf1 mouse modeling. (A ) Traditional Nf1+ /  mice
were generated in which one allele of the murine Nf1 gene is inactivated by
the insertion of a neomycin (neo ) cassette. Nf1+ /  mice can be studied for
tumor predisposition, effects of haploinsufficiency, and genetic cooperativity.
In addition, Nf1+ /  mice can be intercrossed to generate Nf1 /  mice to
analyze the effect of neurofibromin loss on cell transformation and embryonic
development. Nf1 /  cells can be used to generate chimeric Nf1 mice.
(B ) Nf1 mutant mice can also be generated in which specific exons are
deleted. In this regard, the effect of ablation of a particular Nf1 alternatively
spliced exon can be studied. Alternatively, mice can be generated in which a
stop codon is inserted into the alternatively spliced exon to ablate Nf1
expression in tissues that express that particular Nf1 isoform. (C ) Tissue -
specific Nf1 inactivation can be accomplished by the use of Cre / LoxP
technology. Briefly, LoxP recombinatorial sequences are inserted into
noncoding regions of the Nf1 gene to produce phenotypically normal Nf1 flox
mice. Tissue - specific inactivation is mediated by the expression of the
bacteriophage Cre recombinase from a tissue - specific promoter ( e.g.,
synapsin - I promoter ).
Table 1. Nf1 Mouse Models.
Genotype Phenotype Reference
Nf1 /  Embryonic lethality [ 61 -64 ]
Double outlet right ventricle
Exencephaly
Nf1+ /  Tumor development:
pheochromocytoma,
leukemia, lymphoma
[62 ]
Astrogliosis; increased
astrocyte proliferation
[ 75,76 ]
Impaired spatial learning
and memory
[ 80,81 ]
Neuronal Nf1
conditional
knockout
Astrogliosis,
growth retardation
[ 86 ]
Astrocyte Nf1
conditional
knockout
Increased astrocyte
proliferation
Bajenaru et al.,
unpublished
results
Zhu et al.,
unpublished
results
Nf1 exon 23a
knockout
Impaired spatial learning
and contextual discrimination,
delayed motor skill acquisition
[ 85 ]
Nf1 /  chimera Plexiform neurofibromas,
myelodysplasia, neuromotor
defects
[ 82 ]
Nf1+ /  : p53+ /  Malignant peripheral
nerve sheath tumors
[ 82,83 ]
Malignant astrocytomas [84 ]
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has no known function to date. The interaction between
merlin and HRS is intriguing, given the observation that
hepatocyte growth factor (HGF) is one of the most potent
mitogenic factors for Schwann cells. HRS interacts with
merlin better in merlin’s ‘‘open’’ conformation and HRS
overexpression in rat schwannoma cells has the same effect
on cell growth as merlin overexpression [56]. It is not known
whether merlin growth suppression requires HRS.
In addition to growth suppression, merlin is involved in
actin cytoskeleton–mediated processes, such as motility,
spreading, and attachment. Human schwannoma cells
deficient in NF2 expression have dramatic alterations in the
actin cytoskeleton, which can be partially reversed by
attenuation of Rho pathway activity [57] and by wild- type
merlin reexpression [58]. Similarly, overexpression of wild -
type merlin in rat schwannoma cells results in decreased cell
attachment and motility as well as abnormalities in actin
cytoskeleton organization during cell spreading [59]. Sup-
port for a role of merlin in modulating actin cytoskeleton–
mediated processes also derives from experiments on
tumors from Nf2 + /  mice, which were shown to be highly
motile and metastatic [60].
NF Mouse Modeling
A number of distinct approaches have been taken to develop
models for the tumors seen in individuals affected with NF1
(Figure 4 and Table 1). Initial studies focused on the
generation of mice with a targeted mutation in the Nf1 gene.
Second-generation models included Nf1 / chimeric
mice and Nf1 exon-specific knockout mice. Recently,
tissue-specific inactivation of Nf1 has yielded important
insights into the function of neurofibromin in specific cell
types and the consequence of Nf1 loss on tumorigenesis in
NF1. Similar approaches have been taken for the study of
NF2 (Figure 5 and Table 2).
Traditional Nf1 Knockout Mice
Traditional gene- targeted studies initially focused on the
development of mice in which the murine Nf1 gene was
disrupted. Mice heterozygous for a mutation in the Nf1 gene
(Nf1+ / ) are viable and fertile, whereas those homozy-
gous for an Nf1 mutation die during embryonic develop-
ment. The embryonic lethality resulting from homozygous
inactivation of the Nf1 gene reflects the critical role of
neurofibromin during tissue development and organogene-
sis. Nf1 / embryos die of heart failure and edema
secondary to a developmental cardiac vessel defect in
which the aortic and pulmonary outflow vessels remain
fused (double outlet right ventricle) [61,62]. In addition,
some of these mice exhibit neural tube closure defects
(exencephaly) and endocardial cushion abnormalities
[63,64]. The death of Nf1 / embryos between E12.5
and 13.5 precludes an analysis of the role of the Nf1 gene in
postnatal tissues and cell types affected in adults and
children with NF1.
Studies on Nf1 -deficient cell types have demonstrated
that loss of neurofibromin is associated with increased cell
proliferation or survival, increased RAS pathway activation,
and tumorigenesis. Nf1 / Schwann cells exhibit activa-
tion of RAS and but do not initially hyperproliferate in vitro
[65]. After serum removal, individual clones of hyper-
proliferating cells emerge that lose expression of myelin
P0 and display angiogenic and invasive properties [66].
Neurofibromin-deficient fibroblasts also exhibit abnormal
cell proliferation and cannot form perineurium in vitro [67].
In hematopoietic progenitor cells, neurofibromin loss is
associated with increased cell proliferation in response to
multiple mitogenic cytokines, increased RAS pathway
Figure 5. Strategies for Nf2 mouse modeling. (A ) Nf2+ /  mice were
generated by using three different targeting vectors. In the Nf2 mutant allele
generated by McClatchey and associates [ 88 ] the 3 0 part of exon 2 up to the
5 0 part of intron 3 has been replaced by the selection marker leading to a
message that has deleted exons 2 to 4. Giovannini and coworkers [ 87 ]
generated two different mutant Nf2 alleles. One mutant allele, Nf2KO3, was
generated by an insertional mutation in exon 3 leading to a message in which
exon 3 is deleted. The other mutant allele, Nf22, carried an in - frame deletion
of exon 2. ( B ) As for Nf1, tissue - specific Nf2 inactivation can be
accomplished by the use of Cre / LoxP technology [ 91 ]. LoxP recombinatorial
sequences are inserted into noncoding regions flanking exon 2 of the Nf2 gene
to produce phenotypically normal Nf2 flox mice. Tissue - specific inactivation is
mediated by the expression of the bacteriophage Cre recombinase from a
tissue - specific promoter ( e.g., P0 promoter ) or by direct injection of
adenoviral Cre.
Table 2. Nf2 Mouse Models.
Genotype Phenotype Reference
Nf2 /  Embryonic lethality [ 88 ]
Nf2+ /  Tumor development:
osteogenic tumors,
fibrosarcoma,
liver tumors
[ 60,92 ]
P0 -Sch -( 39–121 )
transgenic mice
Schwann cell hyperplasia,
Schwann cell tumors
( schwannoma,
malignant peripheral
nerve sheath tumors )
[ 87 ]
Schwann cell Nf2
conditional
knockout
Schwann cell hyperplasia,
Schwann cell tumors
( schwannoma,
malignant peripheral
nerve sheath tumors )
[ 92 ]
Leptomeningeal
cell Nf2 conditional
knockout
Meningioma [107 ]
Schwann cell Nf2
conditional knockout;
Nf1+ / 
Schwann cell hyperplasia,
Schwann cell tumors
( schwannoma,
neurofibroma,
malignant peripheral
nerve sheath tumors )
Niwa -Kawakita et al.,
unpublished results,
2002
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signaling, and chronic myeloid leukemia [22,68,69]. This
hyperactivation of RAS is mediated in part through
Rac2, which provides cross talk between phosphoinositide
3-kinase (PI -3K) and the Raf-MAPK pathways to modu-
late cell fate [70]. Lastly, in neurons, activation of RAS is
associated with increased cell survival and not proliferation.
Sympathetic ganglion neurons deficient in Nf1 expression
display neurotrophin- independent survival [71] that is
associated with hyperactivation of RAS and its downstream
effector, PI -3K [72,73].
Nf1+ / Mice
Analysis of Nf1+ / mice has yielded some important
insights into NF1 pathophysiology. Nf1+ / animals are
prone to tumor development. By 15 to 18 months of age,
Nf1+ / mice die with leukemias and pheochromocytomas
[61,62]. Loss of the wild- type Nf1 gene can be demon-
strated in these tumors, fulfilling the two-hit hypothesis
proposed by Alfred Knudson for retinoblastoma. In addition,
Nf1+ / mice are more susceptible to carcinogen- induced
pigmentation and papilloma formation [74].
Nf1+ / mice also demonstrate subtle cell growth
abnormalities. Mice heterozygous for a targeted mutation
in the Nf1 gene demonstrate 50%more brain astrocytes with
no effects on other glia populations [75]. In contrast, mice
heterozygous for a targeted mutation in another RAS GAP
molecule, p120-Gap, do not manifest increased astrocyte
numbers. Nf1+ / astrocytes have a cell -autonomous
growth advantage in vitro associated with increased activa-
tion of the downstream RAS effectors, AKT and MAPK [76].
Genetic cooperativity between Nf1 and the p53 and
retinoblastoma cell cycle regulators can be seen in mice
doubly heterozygous for targeted mutations in Nf1 and p53
as well as Nf1 and RB. Nf1+ / astrocytes also display
abnormalities in cytoskeleton-associated processes, includ-
ing motility, attachment and actin cytoskeleton organization
during cell spreading, supporting the notion that some of the
nontumor phenotypes in NF1 may result from additional
alterations in cell physiology, not strictly due to increased cell
proliferation [77]. Similarly, Nf1+ / fibroblasts proliferate
faster in vitro than wild- type fibroblasts, display abnormal-
ities in collagen deposition, and exhibit abnormal wound
healing in vivo [78 ]. As observed with fibroblasts and
astrocytes, Nf1+ / melanocytes and mast cells demon-
strate increased cell proliferation and RAS pathway activa-
tion [79].
Nf1+ / mice exhibit spatial learning deficits reminis-
cent of the specific learning disabilities in children with NF1
[80]. The mechanism for these learning deficits appears to
be related to increased GABA-mediated inhibition and
specific defects in long- term potentiation (LTP) [81].
Decreasing RAS function in Nf1+ / mice reverses both
the inhibition and LTP deficits, suggesting that brain
dysfunction in NF1 might be a direct consequence of
abnormal RAS activation.
Nf1+ / mice develop malignant tumors when bred with
mice heterozygous for a mutation in another tumor suppres-
sor gene, p53. Nf1+ / ;p53+ / mice are prone to the
development of high-grade MPNSTs that are histologically
similar to their human counterparts [82,83]. The spectrum of
tumors in these Nf1+ / ;p53+ / mice can be modulated
by the genetic background of the mouse [84].
Exon-Specific Nf1 Knockout Mice
Mice in which exon 23a has been selectively ablated are
viable, fertile, and do not succumb to tumors, as reported for
Nf1+ / mice. Interestingly, loss of exon 23a results in mice
with significant abnormalities in spatial learning and memory,
similar to Nf1+ / mice [85]. This phenotype is unexpected
given the lack of Nf1 mRNA containing exon 23a in cultured
neurons [29], but clearly argues that exon 23a is important
for neurofibromin’s function in cognition, memory and
learning.
Exon 9a knockout mice have recently been generated
by Alcino Silva and his colleagues (Y. Elgersma and A.
Silva, personal communication). Mice in which Nf1 is
inactivated in exon 9a–expressing neurons, produced by
the insertion of a termination codon in exon 9a, demon-
strate deficits in long- term potentiation and spatial learning,
as well as a slight increase in astrocyte number. In
contrast, ablation of only exon 9a–containing Nf1 results
in mice with normal learning, but a similar increase in
astrocyte number. These results suggest that whereas loss
of neurofibromin in neurons results in learning deficits, exon
9a itself does not appear to be essential for learning and
memory in mice.
Nf1 Chimeric Mice
A limitation to the conventional Nf1 knockout strategy is
the inability to study the growth advantage and tumorigenic
properties of a small population of cells deficient in
neurofibromin expression in the context of the whole
mouse. Two approaches have been taken to circumvent
this problem. The first involves the generation of chimeric
mice in which the developing embryo is composed of a
small number of Nf1 / cells. The chimeric approach
allows one to more accurately model the human condition,
because tumors arising in individuals with NF1 involve small
numbers of cells or clones in which somatic inactivation of
NF1 results in loss of neurofibromin expression. Chimeric
mice composed in part of Nf1 / cells develop neuro-
fibromas, reminiscent of plexiform neurofibromas seen in
patients with NF1 [82]. Similarly, adoptive transfer of Nf1 /
 myeloid cells into an irradiated recipient normal host
induces myeloproliferative disease through hypersensitivity
to granulocyte–macrophage colony - stimulating factor
(GM-CSF) [68].
Conditional Nf1 Knockout Mice
A second approach involves the generation of tissue-
specific conditional knockout mice. Recently, mice have
been generated by Luis Parada and colleagues in which the
Nf1 gene is conditionally disrupted using Cre-LoxP technol-
ogy. In this approach, specific exons of the Nf1 gene are
flanked by LoxP recombinatorial sequences placed in non-
coding introns. These floxNf1 mice are phenotypically
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indistinguishable from wild- type mice because the insertion
of these LoxP sequences does not disrupt Nf1 gene
expression. Inactivation of the Nf1 gene occurs in the
presence of the bacteriophage Cre recombinase enzyme,
which can be expressed in vitro by adenoviral delivery or in
vivo using tissue-specific promoters in transgenic mice.
Several Nf1 conditional knockout mice have been generated
including those with neuron-specific, astrocyte-specific,
and Schwann cell–specific Nf1 inactivation. Ablation of Nf1
in neurons using the synapsin- I promoter results in viable,
growth-retarded pups that exhibit massive brain astrogliosis
and abnormalities in cortical development [86]. The astro-
gliosis in this model appears to be reactive in response to
abnormal neuronal function and is not related to increased
astrocyte proliferation. In contrast, astrocyte-specific Nf1
inactivation appears to be insufficient for astrocytoma
formation, but does confer a significant growth advantage
for astrocytes in vitro and in vivo (Bajenaru, Zhu, Parada, and
Gutmann, unpublished observations). It is not clear whether
the failure to generate astrocytomas reflects additional
genetic events or other cooperating factors necessary for
brain tumor formation in NF1.
Traditional Nf2 Knockout Mice
Two different groups have reported the development of
Nf2 knockout mice [87,88]. In the two studies, similar gene-
targeting approaches were used, with the primary differ-
ences relating to how much of the endogenous Nf2 gene
was deleted during the targeting process (Figure 5 ). In our
approach to model more closely human hereditary (NF2-
related) and sporadic schwannomas in the mouse, we have
initially generated two mouse lines carrying different Nf2
mutant alleles [87]. The first mutant allele, Nf2KO3, was
generated by an insertional mutation in exon 3. This Nf2KO3
allele differed from the mutant allele described by
McClatchey and associates [88], here called ‘‘Nf2KO2–3.’’
In the latter, the 30 part of exon 2 up to the 50 part of intron 3
has been replaced by the selection marker leading to a
message that lacks exons 2 to 3. The second mutant allele,
Nf22, carried an in- frame deletion of exon 2. Both the
Nf2KO3 and Nf22 alleles mimicked two different, naturally
occurring, human mutant NF2 alleles and allowed us to
compare the phenotypic effects of these two human NF2
mutations in mice. Because the three different targeting
approaches resulted in germline Nf2 homozygous mutant
mice, which were not viable, it is likely that all have Nf2
null alleles. Nf2 null mice die early during embryonic
development of a failure to initiate gastrulation as a result
of an absence of organized extraembryonic ectoderm [88].
The underlying defect in these Nf2  /  embryos does
not appear to be related to cell proliferation abnormalities
in the embryo itself, but rather a failure to produce
the extraembryonic structures required to generate a
mesoderm- inducing signal from the embryo proper. The
inability of the developing Nf2 -deficient embryo to generate
or respond to important differentiation cues suggests a role
for the Nf2 protein in cell–cell signaling events critical for
extraembryonic formation.
Heterozygosity for any of the three mutant alleles leads
to a high incidence of bone tumors showing loss of the wild-
type Nf2 allele. However, differences were observed
with respect to the grade of malignancy. Metastases of
osteosarcoma were found less frequently in Nf2KO3 / + and
Nf22 / + mice in comparison to the mice described by
McClatchey and associates [60] (29% vs. 95%, P<0.0001,
in case of Nf2KO3 / + mice). The different time windows of the
histologic analyses may account for this difference, because
mice were followed up to 24 months in our study and up to 30
months in the study of McClatchey and colleagues. The
finding of osteomas inNf2KO3 / + andNf22 / + mice contrasts
with the absence of benign bone tumors described by
McClatchey [60]. This difference might be explained by the
use of different genetic backgrounds. Regardless, our data
indicate that Nf2mutant alleles lacking only exon 2 or exon 3
do not permit normal embryonic development and lack
tumor-suppressor properties. Thus, both exon 2 and exon 3
carry sequences that are essential for Nf2 function and
regardless of the mutation type, all three hemizygous mice
do not show clinical features of human NF2. In particular they
demonstrate a tumor spectrum that differs significantly from
that observed in NF2 patients. Therefore, these animals do
not accurately recapitulate the cognate human genetic
disease.
Schwannomas and Schwann Cell Hyperplasia Are Induced
by Overexpression of a Mutant Nf2
When transiently expressed in various cell types, mutant
proteins corresponding to naturally occurring NF2 mutations
demonstrate distinct subcellular localizations [36,89,90].
C- terminal deletion mutants of various lengths remain
located at the cell membrane. In contrast, mutants with an
intact C- terminal domain but with a deleted or altered N-
terminal domain are mislocalized mainly to the perinuclear
cytoplasmic region. Such mislocalization was observed for a
mutant protein modeled from naturally occurring mutations
where exons 2–3 are deleted without a frameshift, Sch-
(39–121) [36].
To develop a system by which to identify functional
domains of the NF2 protein that may play a role in merlin
growth suppression, we have generated transgenic mice
expressing various Nf2 mutants under the control of the
Schwann cell -specific P0 promoter [91], including a mutant
schwannomin modeled from a naturally occurring mutation,
Sch-(39–121) and a mutant schwannomin prototypic for
C- terminal deletion mutants, Sch-Cter. Mice expressing
Sch-(39–121) showed a high prevalence of Schwann
cell–derived tumors and Schwann cell hyperplasia, whereas
those expressing Sch-Cter were normal [87]. These
results indicate that a subset of mutant NF2 alleles observed
in patients may encode products with dominant -negative
properties when overexpressed in specific cell lineages.
However, the endogenous expression level of a mutant Nf2
allele may not be sufficient to elicit this ‘‘potential’’ oncogenic
effect. Indeed, proteins generated from endogenous mutant
alleles in Nf2KO3 / + and Nf22 / + mice are hardly detectable
and recent data demonstrate that mutant products of
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endogenous alleles are efficiently degraded by the ubiquitin -
dependent proteasome pathway (Gautreau et al., submitted
for publication, 2002).
Conditional Nf2 Knockout Mice
To examine the consequences of Nf2 -deficiency in
selected cell types of adult mice, we have generated a
conditional Nf2 allele (Nf2 flox2 ) [92]. Upon successive
matings with transgenic P0-Cre mice, the Nf2 conditional
mutant mice recapitulate several features observed in NF2
patients, specifically Schwann cell hyperplasia, Schwann cell
tumors, cataracts, and cerebral calcifications (Figure 6 ). All
these manifestations have been exclusively observed in
mice with both alleles of theNf2 gene inactivated in Schwann
cells and in a subset of neural crest cells. Meningioma, the
second tumor hallmark of human NF2, was not observed in
these mice, suggesting that this tumor originates from cells
that do not express the P0 protein. To determine whetherNf2
disruption is also sufficient for meningioma formation, we
inactivated Nf2 in homozygous conditional knockout mice by
adenoviral Cre delivery. Mice with arachnoidal cell Cre-
mediated excision of Nf2 exon 2 developed a range of
meningioma subtypes histologically similar to the human
tumors [107].
Conditional Nf2 knockout mice also provide a powerful
tool for investigating genetic interactions and tumorigenic
cooperativity. In an attempt to assess the cooperativity of the
Nf2 gene with other cancer-associated genes, we and
others have crossed Nf2 mutant (germline or conditional )
mice to other strains of knockout mice. In such crosses, if the
offspring containing both parental oncogenic alleles develop
tumors faster or of a different type than either tumor-prone
parent, then genetic cooperativity is operative. The identi-
fication of cooperating tumor suppressor genes, which
synergize with Nf2 loss, can provide important mechanistic
insights into Nf2 -associated tumorigenesis pathways. Table
2 describes the results from some representative crosses
performed to date. Remarkably, some crosses result in
accelerated tumorigenesis in the bitransgenic offspring
compared to either parent. For example, mice carrying two
mutant Nf2 (conditional; P0 ) and one Nf1 null allele(s) not
only show accelerated tumorigenesis, but also exhibit novel
tumor types (e.g., neurofibroma) not seen in the parental
mutant mice.
Figure 6. Schwannomas and Schwann cell hyperplasia in P0CreC;Nf2 flox2 / flox2 mice. (A ) Schwannoma in the uterus of a P0CreC;Nf2 flox2 / flox2 mouse. The tumor
appeared as a rather uniform Schwann cell growth extending from the corpus uteri to the uterine horns in combination with (B ) Schwann cell hyperplasia in the
peripheral part of the myometrium showing strong S -100 protein immunoreactivity. (C ) Ultrastructural examination of the tumor demonstrated Schwann cells
(Schwann cell nucleus denoted by N ) with long, thin cytoplasmic processes (arrow ), which was variably associated with a basement membrane (BM).
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Future Approaches
The failure of Nf1+ / and Nf2+ / knockout mice to
develop tumor spectra similar to the human conditions
reflects the major limitation of first -generation knockout
modeling strategies. The generation of mouse models that
accurately mimic the human disease requires additional
sophisticated approaches, such as tissue-specific and
conditional mutations. However, the failure of astrocyte-
specific knockout mice to develop astrocytomas indicates
that even the newest generation of mouse model has a
number of limitations (Figure 7 ).
First, NF1-associated astrocytomas typically occur in
specific brain regions (optic nerve, chiasm, hypothalamus,
and brainstem). It is possible that not all regions of the brain
are permissive for NF1-associated brain tumor formation. In
this regard, pilocytic astrocytomas in NF1 typically occur
within the optic pathway, whereas in the general population,
the most frequent brain location for a pilocytic astrocytoma is
the cerebellum. Astrocytes from different regions of the brain
have been reported to have differing responses to agents
that elevate cyclic AMP [93], regional specificity in gap
junction coupling [94], differences in glutamate and seroto-
nin uptake [95], and distinctive growth patterns [96]. Future
studies aimed at inactivating Nf1 specifically in cerebellar or
optic nerve astrocytes might be useful in determining the
importance of regional differences in astrocyte biology or
brain environment.
Second, the cell of origin of the pilocytic astrocytoma may
not be a type 1 fibrillary astrocyte, based on recent studies
demonstrating gene expression similarities between pilocytic
astrocytomas and oligodendrocyte–astrocyte precursors
[103]. Pilocytic astrocytomas represent a unique grade of
glial neoplasm that does not progress to a fibrillary
astrocytoma. Several studies have highlighted these inher-
ent differences, both with regard to genetic changes and glial
cell protein expression patterns [97-101]. For instance,
pilocytic astrocytomas express the unique PEN5 epitope
shared with cells and tumors of an oligodendrocyte lineage
[102]. This marker is not expressed in fibrillary astrocytes or
astrocytomas. Recent studies from our laboratory have
demonstrated expression of oligodendrocyte-associated
transcripts, such as PLP, PMP-22, MBP, and oligodendro-
cyte myelin glycoprotein (OMgP) in pilocytic astrocytomas,
suggesting that these tumors have at least some gene
expression features of oligodendrocyte- type 2 astrocyte
(O2A) cells [103]. In this regard, it may be necessary to
inactivate Nf1 in the correct progenitor cell, perhaps an O2A
lineage cell, to generate NF1-associated astrocytomas in
mice.
Third, NF1-associated astrocytomas do not develop in
the context of a genetically normal (Nf1+ / + ) brain environ-
ment. In contrast, these tumors develop in a brain environ-
ment in which the rest of the brain is Nf1+ / . In the
neurofibroma, it has been suggested thatNf1+ / mast cells
and fibroblasts play a role in tumorigenesis. Another
environmental effect is the contribution of modifying genes
to tumor development. In the case of glioblastoma, Reilly et
al. observed genetic background-specific effects on the
spectrum of tumors in Nf1+ / ;p53+ / mice [84]. Further
work will be required to formally address this genetic
environment effect as well as the mechanisms that underlie
the modifier gene effect on tumor spectrum.
Lastly, it is possible that NF1-associated astrocytomas
only form when other cooperating genetic alterations are
present. It is unlikely that these additional genetic events are
the common alterations seen in high-grade astrocytomas,
like p53 loss [101], despite the observation that high-grade
glioblastomas form in mice doubly heterozygous for muta-
tions in both Nf1 and p53 [84]. Work is ongoing in many
laboratories using gene and protein expression profiling
technologies to identify subtle cooperating factors that
promote or inhibit tumorigenesis. The characterization of
these additional proteins may provide additional targets for
rational drug design for the effective management of tumors
in NF1.
In the case of NF2 modeling, the refinement of current
targeting approaches has allowed the generation of relevant
models of NF2-related tumor development and provides
powerful tools for investigating meningioma progression and
for the preclinical evaluation of potential therapeutic inter-
ventions. In particular, the availability of arachnoid cell–
specific Nf2 conditional mutant mice will greatly facilitate the
elucidation of the critical genetic factors that influence
meningioma development and progression.
Recently, inactivation of Protein 4.1B (or DAL-1), a
second protein 4.1–related tumor suppressor, was identified
as an early event in meningioma tumorigenesis [104,105]. In
contrast to NF2, Protein 4.1B loss occurs in meningiomas
and not in schwannomas [104], and overexpression of
Protein 4.1B suppresses meningioma cell line proliferation,
but has no effect on schwannoma cell line growth in vitro
[106]. Further work will need to be performed to determine
the relationship of merlin loss to Protein 4.1B expression as
well as the contribution of Protein 4.1B to meningioma
pathogenesis in the mouse. The generation of a preclini-
cal mouse model for meningiomas through the targeted
Figure 7. Development of future mouse models for NF1 -associated tumors.
The formation of tumors or cancer requires a number of events, both genetic
and environment, that culminate in tumorigenesis. First, Nf1 inactivation must
occur in the correct cell of origin at the proper developmental time. In some cell
types, the timing of inactivation might be critical. Second, in the brain, some
regions might be permissive for tumor development. This permissiveness may
reflect genetic factors, regional differences in cellular composition, and brain
environment. Third, cooperating genetic changes may influence tumor
expansion. These genetic changes might be subtle genetic alterations, not
previously thought to be conventional initiating events for tumorigenesis, or
modifying loci that promote tumor formation.
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disruption of the Protein 4.1B and Nf2 genes could facilitate
the assessment of potential targeted therapies for this
common brain tumor in NF2.
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